Neurocrine Biosciences, Inc. (NBIX)
133.25
+4.84
(+3.77%)
USD |
NASDAQ |
Apr 17, 16:00
132.75
-0.50
(-0.38%)
Pre-Market: 08:30
Neurocrine Biosciences SG&A Expense (Quarterly) : 301.80M for Dec. 31, 2025
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| Soleno Therapeutics, Inc. | 40.88M |
| Glaukos Corp. | 94.70M |
| Edgewise Therapeutics, Inc. | 12.38M |
| Nuvalent, Inc. | 34.43M |
| Biogen, Inc. | 682.50M |